Status: Not yet recruiting
mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line
In second line with advanced or recurrent biliary tract cancer refractory to first line gemcitabine plus cisplatin,efficacy of mFOLFOX/FOLFIRI vs mFOLFOX will be evaluated at randomized phase 2 trial.
Participants needed: 130
Trial details
Phase: Phase 2Age: 19-99Biological sex: AllType: InterventionalSponsor: Seoul National University Bundang HospitalUpdated: May 28, 2026Locations: 1
Eligibility criteria
Age ≥ 19 years. [+7]
Patients with prior exposure to oxaliplatin or irinotecan in previous cancer tre... [+14]